Priya Kumari and Shivani Tomar
Introduction
This study investigates Teriflunomide's potential to mitigate brain atrophy and its impact on cognitive function in MS patients.
Method
The study combines a case study and a cohort study. The case involves a 60-year-old woman with MS experiencing cognitive decline despite a stable EDSS score. The cohort consisted of 46 clinically stable Multiple Sclerosis (MS) patients who received teriflunomide treatment. Brain atrophy markers and cognitive function were evaluated.
Results
The case study patient showed signs of cognitive decline on the SDMT. The cohort study revealed teriflunomide treatment did not affect the corpus callosum index but resulted in a significant increase in third ventricle width, a potential indicator of brain atrophy.
Conclusion
Teriflunomide may offer benefits in mitigating brain atrophy in MS. The study proposes using declining Symbol Digit Modalities Test (SDMT) scores to proactively identify MS progression and suggests teriflunomide as a potential treatment approach. Further research is needed to confirm the link between teriflunomide and cognitive improvement.